OneMedNet expands its cardiovascular network by adding 85 centers, enhancing real-world data for healthcare innovation and insights.
Quiver AI Summary
OneMedNet Corporation has significantly expanded its Cardiovascular network by adding 85 new cardiovascular centers and data sources, making it one of the largest providers of Real-World Data (RWD) in this domain. Given that cardiovascular diseases are the leading cause of death globally and impose substantial economic burdens, OneMedNet's enriched multimodal data network is poised to benefit pharmaceutical and insurance sectors by offering real-time insights into disease progression, treatment responses, and clinical outcomes. This expansion allows OneMedNet to deliver high-quality, regulatory-grade data, including de-identified imaging and diagnostic reports, at an unprecedented scale. CEO Aaron Green emphasized that this clinically rich data is essential for accelerating innovation in diagnostics and therapeutics, while the company's iRWD™ platform harnesses the potential of over 1,750 healthcare sites to drive breakthroughs across various medical fields.
Potential Positives
- OneMedNet expands its Cardiovascular network by adding 85 centers and data sources, solidifying its position as one of the largest providers of Cardiovascular Real-World Data.
- The expansion provides pharmaceutical and insurance sectors with enriched multimodal cardiovascular data, enhancing their ability to make evidence-based decisions in drug development and patient care.
- OneMedNet's network offers de-identified data that reflects the latest clinical insights, making it a valuable resource for life sciences companies, AI developers, and medical device manufacturers.
- The press release highlights the company's commitment to improving patient outcomes and innovation by delivering high-quality, regulatory-grade cardiovascular Real-World Data at scale.
Potential Negatives
- The reliance on forward-looking statements could lead to investor skepticism about the company's future performance, as these statements are subject to numerous risks and uncertainties that could materially affect actual results.
- The mention of Bitcoin and associated risks in the context of their treasury strategy introduces potential volatility and financial risk that may concern investors.
- The company does not provide specific details on how the addition of new cardiovascular centers will directly impact its financial performance or market share, leaving gaps in transparency for stakeholders.
FAQ
What is OneMedNet's recent expansion in cardiovascular data?
OneMedNet announced the addition of 85 cardiovascular centers to its network, positioning it among the largest providers of cardiovascular Real-World Data.
How does OneMedNet enhance drug development?
The enriched multimodal cardiovascular data provides insights into disease progression, treatment responses, and outcomes, accelerating evidence-based R&D for pharmaceuticals.
Why is cardiovascular Real-World Data important?
Cardiovascular diseases are the leading cause of death globally, making accurate RWD crucial for improving patient outcomes and supporting clinical evidence generation.
What types of data does OneMedNet provide?
OneMedNet offers de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) that are continually updated for clinical relevance.
Who can benefit from OneMedNet's data network?
Life sciences companies, AI developers, medical device manufacturers, and the pharmaceutical sector can all leverage OneMedNet's high-quality cardiovascular RWD.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ONMD Hedge Fund Activity
We have seen 5 institutional investors add shares of $ONMD stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP added 182,638 shares (+inf%) to their portfolio in Q2 2025, for an estimated $104,121
- CKW FINANCIAL GROUP removed 100,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $57,010
- EXENCIAL WEALTH ADVISORS, LLC added 45,448 shares (+3.1%) to their portfolio in Q2 2025, for an estimated $25,909
- XTX TOPCO LTD added 35,900 shares (+inf%) to their portfolio in Q2 2025, for an estimated $20,466
- CITADEL ADVISORS LLC removed 28,058 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,995
- GEODE CAPITAL MANAGEMENT, LLC removed 15,869 shares (-10.4%) from their portfolio in Q2 2025, for an estimated $9,046
- VIRTU FINANCIAL LLC removed 14,515 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $8,275
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MINNEAPOLIS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD), announced the addition of 85 cardiovascular centers and data sources, expanding its Cardiovascular network thereby positioning OneMedNet as one of the largest providers for Cardiovascular Real-World data.
Cardiovascular diseases (CVDs) remain the world’s leading cause of death, responsible for approximately 19.8 million deaths in 2022, accounting for roughly 32% of all global mortality 1 . Economically, the burden is staggering: CVD drives an estimated $320 billion annually in the United States alone, and more than $1 trillion globally each year in direct healthcare costs and lost productivity 2 .
Such pervasive health and financial pressures make OneMedNet’s enriched multimodal cardiovascular data network ideally suited for pharmaceutical and insurance sectors. For drug developers, this real-time, expansive data offers deeper insights into disease progression, treatment responses, and outcomes—fueling more efficient, evidence-based R&D and accelerating the development of novel therapeutics.
This expansion enhances OneMedNet’s network, delivering de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) at unprecedented scale and clinical depth to life sciences companies, AI developers, and medical device manufacturers, with data that is continually updated to reflect the latest clinical insights and advancements.
The addition of these new sites solidifies OneMedNet’s position as the premier source for high-quality, regulatory-grade cardiovascular RWD, fueling innovation, supporting clinical evidence generation, and improving patient outcomes through the most robust ecosystem in the industry.
“By combining de-identified cardiovascular imaging, structured reports, and ECG signals from this vast network, we’re providing real-world clinical insights that accelerate innovation in diagnostics, therapeutics, and AI model development. This is the clinically rich, longitudinal data the industry has been demanding—and we’re delivering it at scale, with continual updates ensuring the most current and relevant information,” said Aaron Green, President and CEO of OneMedNet.
- World Health Organization Cardiovascular Disease – https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29
- World Heart Federation 2025 Report - https://world-heart-federation.org/resource/world-heart-report-2025/
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. We base these forward-looking statements on our current expectations and projections about future events, which we derive from the information presently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]